Business Context and Reporting Period
This Form 8-K Current Report was filed by Mangoceuticals, Inc. on November 11, 2024. The company is incorporated in Texas and its common stock trades on the Nasdaq Capital Market under the symbol MGRX. The report primarily addresses a new executive compensation arrangement effective October 1, 2024.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the specific compensation terms of the new Consulting Agreement:
- Monthly Cash Compensation: $4,000
- Equity Grant: 25,000 shares of common stock (vested immediately upon execution)
- Expense Reimbursement: Allowed with pre-approval required for expenses exceeding $500
Material Changes
The material change reported is the formalization of a Consulting Agreement with Eugene M. Johnston, the Company's Chief Financial Officer. While the agreement was signed on November 11, 2024, it is retroactively effective as of October 1, 2024. This establishes a 12-month term for Mr. Johnston's services.
Outlook, Risks, and Management Commentary
Management Commentary: The agreement includes provisions for discretionary equity bonuses and/or cash awards at the discretion of the Compensation Committee or Board of Directors. Compensation may be increased in the future without amending the agreement.
Termination and Risks: The agreement may be terminated early by mutual approval, for cause (with a 30-day cure period), or by Mr. Johnston at any time for any reason. The contract includes standard non-solicitation covenants for the term of the agreement plus 12 months thereafter.
Investor Verification Checklist
- Verify the immediate impact of the 25,000 share grant on total outstanding shares and potential dilution.
- Review the full text of the Consulting Agreement (Exhibit 10.1) for specific non-solicitation and confidentiality clauses.
- Monitor future filings for any discretionary bonuses or compensation increases granted to the CFO.
- Confirm the company's cash position to ensure it can sustain the new monthly cash outflow alongside existing operational costs.